Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study on the Efficacy and Safety of CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients Who Have Completed Adjuvant Anti-HER2 Targeted Therapy"

NCT07019363 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07019363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07019363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study on the Efficacy and Safety of CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients Who Have Completed Adjuvant Anti-HER2 Targeted Therapy"
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Recruiting
Start date
June 15, 2025
Completion date
April 15, 2033
Enrollment
1,903 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy, breast cancer